At least one-third of the world's population has been infected with the hepatitis B virus (HBV), and 400 million people are chronic carriers. In most populations, chronic HBV infection is the ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Use the tweezers to pull out a segment of DNA from the hepatitis B virus. A subunit vaccine makes use of just a small portion of a pathogen. For a virus, the vaccine can contain just a piece of ...

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...

As a briefer, hepatitis B is a virus that affects the liver and results ... This is significant on the background of an existing screening and nationwide immunization program.

Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4-13 years of age in 363 ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

However, it is preventable because the major risk factors have already been identified. Among the factors that increase the risk of primary liver cancer include chronic infection with hepatitis B or C ...